Cardinal Health Recalls Webcol Alcohol Prep Pads Due to Microbial Contamination
Cardinal Health is voluntarily recalling select lots of Webcol™ Large Alcohol Prep Pads due to microbial contamination with Paenibacillus phoenicis. The recall is being conducted to the consumer level due to the risk of serious infections. The product was distributed nationwide and internationally.
Swissmedic: Lisdexamfetamine Contraindication for Pheochromocytoma Patients
Swissmedic is updating the contraindications for lisdexamfetamine dimesylate to include patients with pheochromocytoma. This change aims to prevent potentially life-threatening increases in catecholamine levels. The product information for both healthcare professionals and patients will be amended to reflect this new contraindication.
WHO Guidance on Responsible AI in Mental Health
The WHO has released guidance based on expert recommendations for the responsible use of AI in mental health. The guidance emphasizes recognizing generative AI use as a public mental health concern, integrating mental health into AI impact assessments, and co-designing AI tools with experts and individuals with lived experience.
Medicaid Fraud Control Units Annual Report: FY 2025
The HHS OIG has released its annual report for Medicaid Fraud Control Units (MFCUs) for Fiscal Year 2025. The report details nearly $2 billion in combined criminal and civil recoveries, 1,185 convictions, and 900 exclusions from federal health care programs. It highlights trends in fraud and patient abuse investigations and prosecutions.
ANSM Safety Alert: Eonis SCID-SMA Kit for Genetic Testing
The French ANSM has issued a safety alert regarding the Eonis SCID-SMA kit for genetic testing, manufactured by Wallac/Revvity. Affected users have been notified directly by the company, and the alert is registered under ANSM reference R2607970.
Philips Radiology Device Safety Alert
The French ANSM has been informed of a safety action initiated by Philips Medical Systems Nederland BV concerning radiology devices. Affected users have received a direct communication from the company regarding this action, registered under ANSM reference R2606927.
FDA Seeks Comment on Priority Voucher Pilot Program
The FDA has published a Federal Register Notice seeking public comment on its Commissioner's National Priority Voucher pilot program. The agency also announced a public hearing on June 12, 2026, to gather stakeholder feedback on various aspects of the program's implementation and effectiveness.
Wisconsin Pharmacy Board Rule Updates and Enforcement Actions
The Wisconsin Pharmacy Examining Board has updated administrative rules effective August 1, 2020, affecting rule chapters Phar 6 (Storage) and Phar 17 (Internships). These updates include adoption orders outlining specific changes to storage requirements and internship regulations for licensed pharmacists and interns in Wisconsin.
Wisconsin Pharmacy Board Rule Changes
The Wisconsin Pharmacy Examining Board has updated Chapter Phar 7, concerning the Practice of Pharmacy, with changes effective January 1, 2021. These updates were adopted on June 4, 2020, and provide important information for licensees regarding pharmacy practice regulations.
Wisconsin Pharmacy Board Activities: PDMP, HOPE, Opioid Treatment
The Wisconsin Pharmacy Board is providing an update on its activities, including the implementation of the Prescription Drug Monitoring Program (PDMP), participation in the Heroin, Opiate Prevention and Education (HOPE) legislation, and significant rewrites of Chapters 7 (Pharmacy Practice) and 15 (Sterile Pharmaceuticals) of its rules. The PDMP has seen substantial provider registration and inquiry volume, aiming to curb controlled substance abuse.
Wisconsin Pharmacy Board Updates and Rule Changes
The Wisconsin Pharmacy Examining Board issued a newsletter on September 17, 2020, providing updates on rule changes, COVID-19 variances, and enforcement actions. A key update concerns changes to administrative rules in Chapter Phar 7, effective January 1, 2021.
DEA Virtual Assembly on Fentanyl Risks
The DEA Omaha Division is promoting a free virtual assembly on fentanyl and fake pill risks for middle and high school educators. The event is scheduled for April 7, 2026, and aims to educate attendees on the dangers associated with these substances.
DEA Seizes 4.7M Fentanyl Pills and 2,396 lbs Powder
The DEA announced the seizure of over 4.7 million fentanyl pills and nearly 2,396 pounds of fentanyl powder during Phase 2 of Operation Fentanyl Free America. This operation removed over 57 million deadly doses of fentanyl from communities across the United States.
DEA Miami Combats Illicit Vape and Edible Products
The DEA Miami and Tampa Field Divisions are actively combating illicit vape and edible products containing dangerous controlled substances. This initiative highlights ongoing enforcement efforts to protect community members from these harmful products.
Massachusetts Pharmacist Administration of Medications Guidance
The Massachusetts Department of Public Health issued guidance allowing pharmacists and pharmacy interns to administer additional medications, including testosterone for gender-affirming care, and treatments for HIV and STIs. This guidance replaces a previous version and provides details on eligibility and administration requirements.
Massachusetts Pharmacist Medication Administration Guidance Update
The Massachusetts Department of Public Health issued a circular letter updating guidance on pharmacist medication administration. This update authorizes pharmacists to administer testosterone for gender-affirming care, and medications for the prevention and treatment of HIV and sexually transmitted infections, in addition to existing authorizations for mental illness and substance use disorder treatments.
Center for Scientific Review Notice of Closed Meetings
The National Institutes of Health, through the Center for Scientific Review, has published a notice announcing upcoming closed meetings. These meetings are scheduled for April 16, 2026, and involve discussions that are not open to the public.
Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) has issued a notice regarding exempt chemical preparations under the Controlled Substances Act. This notice opens a 60-day public comment period for interested parties to submit their views on the matter.
NIH Government Inventions Available for Licensing
The National Institutes of Health (NIH) has published a notice announcing the availability of government-owned inventions for licensing. This notice provides information for parties interested in obtaining licenses for these inventions.
NIH Center for Scientific Review Closed Meetings Notice
The National Institutes of Health (NIH) has published a notice regarding upcoming closed meetings for the Center for Scientific Review. These meetings are scheduled for April 16, 2026, and are part of the standard operational procedures for reviewing grant applications.
National Human Genome Research Institute Meeting Notice
The National Institutes of Health (NIH) published a notice announcing an upcoming meeting for the National Human Genome Research Institute. The meeting is scheduled to take place on May 18-19, 2026. This notice serves as an informational announcement regarding the meeting details.
FDA CDRH Variance Approval Letter to Smack Shack
The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to Smack Shack. This document grants a specific variance, the details of which are not publicly available in the provided text.
FDA Acknowledgment Letter to Whisky A Go Go
The Food and Drug Administration (FDA) has issued an acknowledgment letter to Whisky A Go Go. The letter, originating from the Center for Devices and Radiological Health (CDRH), confirms receipt of correspondence but provides no further details on its content or implications.
FDA Complaint Posted for Public Comment
The FDA has posted a complaint for public comment, with the comment period closing on March 19, 2026. The document is available on Regulations.gov, though no content is directly viewable, only an attachment labeled 'Complaint' from the author CTP.
FDA Complaint Filed
The FDA has filed a complaint regarding a matter related to its regulatory oversight. The document indicates that comments were closed on March 19, 2026. No specific details about the complaint's nature or the parties involved are available in the provided metadata.
FDA Variance Application - Furew Floral Event and Landscaping
The Food and Drug Administration (FDA) has received a variance application from Furew Floral Event and Landscaping. The application, submitted by CDRH, is available for review on Regs.gov.
FDA Letter to U.S. Patent and Trademark Office
The Food and Drug Administration (FDA) has posted a letter addressed to the U.S. Patent and Trademark Office. The document is available on Regulations.gov and was authored by the Center for Drug Evaluation and Research (CDER).
FDA Letter to U.S. Patent Office
The Food and Drug Administration (FDA) has issued a letter to the U.S. Patent and Trademark Office. The letter is authored by CDER and was posted on March 19, 2026. No documents are available for viewing or download.
FDA Letter to Patent Office
The Food and Drug Administration (FDA) has issued a letter to the U.S. Patent and Trademark Office (USPTO). This communication is related to the Center for Drug Evaluation and Research (CDER) and is part of the FDA's ongoing regulatory processes. The comment period for this notice has closed.
FDA Variance Application from JSMJ Group LLC
The FDA has received a variance application from JSMJ Group LLC. The application pertains to medical device regulations. No documents are currently available for viewing or download.
FDA Variance Application from Kenyon Productions, LLC Closed
The Food and Drug Administration (FDA) has closed a variance application submitted by Kenyon Productions, LLC. The specific details of the variance and the reasons for its closure are not provided in the available document.
FDA Completeness Assessment Correspondence
The FDA has issued a completeness assessment correspondence to Hyman, Phelps & McNamara, P.C. regarding a submission. The document is a standard communication within the drug approval process and does not contain new regulatory requirements or guidance.
FDA Variance Application from Jennifer Rishel
The FDA has posted a variance application submitted by Jennifer Rishel. The application, filed by CDRH, is available in redacted format on regulations.gov. No specific details on the nature of the variance or its implications are provided in the posting.
FDA Variance Approval Letter to DJ Ken-E. Ken
The Food and Drug Administration (FDA) has posted a Variance Approval Letter related to DJ Ken-E. Ken. The document was issued by the Center for Devices and Radiological Health (CDRH). No other details or documents are available for viewing.
FDA Variance Amendment from Furew Floral Event
The FDA has posted a variance amendment related to the Furew Floral Event and Landscaping. This document, authored by CDRH, is available for review on Regulations.gov. No specific compliance actions or deadlines are detailed in the provided information.
FDA CDRH Variance Approval Letter to Furew Floral
The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to Furew Floral Event and Landscaping. This document signifies an approval for a specific variance requested by the company.
FDA Variance Amendment from Leo Weeks Photographers
The FDA has posted a variance amendment submitted by Leo Weeks Photographers. The document is available for review on Regulations.gov, though no specific details or full text are provided directly in the listing.
FDA Variance Amendment from Whisky A Go Go
The Food and Drug Administration (FDA) has posted a variance amendment related to "Whisky A Go Go." The document is available for review on regulations.gov, though no specific details or downloadable content are provided directly in the listing.
FDA Approves Higher Dose Wegovy (semaglutide) for Weight Loss
The FDA has approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, known as Wegovy HD, for weight management in certain adults. This approval was granted under the Commissioner's National Priority Voucher pilot program, aiming to expedite treatments for national health priorities.
Ortho Connect Medical Device Recall for Incorrect Test Results
Health Canada has issued a Type II recall for the Ortho Connect medical device manufactured by Biomedical Data Solutions Limited due to the potential for incorrect test results. The recall affects specific lot and model numbers, with a recall date of February 19, 2026.
UniCel DxI 600 Total T4 Assay Recall
Health Canada has issued a Type II recall for the UniCel DxI 600 Access Immunoassay System-Total T4 Assay due to a negative bias that can cause false low patient results. The recall affects specific lot numbers and poses a medium safety risk. Healthcare providers are advised to contact the manufacturer for further information.
Health Canada: Nitrous Oxide Chargers Sold for Inhalation Without Authorization
Health Canada has issued a recall for Nitrous Oxide Chargers sold by Polar Imports Canada for inhalation without market authorization. The agency warns consumers not to inhale these products for recreational purposes and to seek medical attention if side effects occur.